Key facts
- Avigen’s last known valuation is $2.2M (Mar 2025).
- It has raised $390K; the latest was Accelerator/Incubator in May 2025.
- Notable investors include SFC Capital, British Business Bank, ICURe, Imperial White City Incubator.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Avigen
- ·The full record, as it builds
Funding rounds
No funding rounds for Avigen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avigen
Operator of an immunotherapy firm intended to accelerate immune cell development. The company leverages the total molecular binding strength between immune cells and their target cells for the precise selection of potent immune candidates, enabling healthcare professionals to make earlier and more confident decisions that speed up and de-risk cell therapy development.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2025
- Website
- avigen.bio/
- Ownership
- Privately Held (backing)
Avigen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avigen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avigen in its N-PORT filings yet. We sweep new filings monthly.